Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Forecasted to Post Q1 2025 Earnings of $1.28 Per Share

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) – Equities researchers at William Blair issued their Q1 2025 earnings estimates for Neurocrine Biosciences in a research note issued to investors on Tuesday, April 23rd. William Blair analyst M. Minter anticipates that the company will earn $1.28 per share for the quarter. The consensus estimate for Neurocrine Biosciences’ current full-year earnings is $4.84 per share. William Blair also issued estimates for Neurocrine Biosciences’ Q2 2025 earnings at $1.56 EPS, Q3 2025 earnings at $1.75 EPS and Q4 2025 earnings at $1.99 EPS.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings data on Wednesday, February 7th. The company reported $1.44 EPS for the quarter, beating analysts’ consensus estimates of $1.13 by $0.31. The firm had revenue of $515.20 million for the quarter, compared to analyst estimates of $518.52 million. Neurocrine Biosciences had a return on equity of 12.85% and a net margin of 13.23%. The business’s quarterly revenue was up 25.0% compared to the same quarter last year. During the same period last year, the company earned $0.88 EPS.

Several other brokerages have also recently weighed in on NBIX. StockNews.com raised Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a report on Thursday, February 8th. Barclays raised their price objective on shares of Neurocrine Biosciences from $145.00 to $150.00 and gave the company an “overweight” rating in a research note on Tuesday, January 23rd. HC Wainwright reiterated a “buy” rating and set a $150.00 target price on shares of Neurocrine Biosciences in a research report on Wednesday. JPMorgan Chase & Co. raised their price target on Neurocrine Biosciences from $148.00 to $158.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 20th. Finally, The Goldman Sachs Group upped their price objective on Neurocrine Biosciences from $134.00 to $153.00 and gave the company a “buy” rating in a report on Thursday, January 25th. Six research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $142.38.

Neurocrine Biosciences Stock Down 1.3 %

Shares of NBIX opened at $135.99 on Thursday. The stock’s fifty day simple moving average is $136.63 and its 200-day simple moving average is $127.85. The firm has a market capitalization of $13.53 billion, a PE ratio of 56.19 and a beta of 0.25. Neurocrine Biosciences has a 12-month low of $89.04 and a 12-month high of $148.37.

Insider Activity at Neurocrine Biosciences

In other Neurocrine Biosciences news, CEO Kevin Charles Gorman sold 2,707 shares of the business’s stock in a transaction that occurred on Wednesday, January 31st. The stock was sold at an average price of $140.69, for a total transaction of $380,847.83. Following the transaction, the chief executive officer now owns 502,188 shares of the company’s stock, valued at approximately $70,652,829.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, Director Richard F. Pops sold 15,000 shares of Neurocrine Biosciences stock in a transaction dated Tuesday, February 20th. The stock was sold at an average price of $132.47, for a total transaction of $1,987,050.00. Following the completion of the transaction, the director now owns 29,512 shares in the company, valued at $3,909,454.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Kevin Charles Gorman sold 2,707 shares of the business’s stock in a transaction that occurred on Wednesday, January 31st. The stock was sold at an average price of $140.69, for a total value of $380,847.83. Following the transaction, the chief executive officer now directly owns 502,188 shares in the company, valued at approximately $70,652,829.72. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 186,994 shares of company stock valued at $25,806,409. Insiders own 4.40% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Mather Group LLC. bought a new position in Neurocrine Biosciences during the first quarter worth $26,000. Lindbrook Capital LLC boosted its holdings in shares of Neurocrine Biosciences by 85.0% during the 4th quarter. Lindbrook Capital LLC now owns 209 shares of the company’s stock worth $28,000 after buying an additional 96 shares during the period. EdgeRock Capital LLC acquired a new position in Neurocrine Biosciences in the 4th quarter valued at about $31,000. Benjamin F. Edwards & Company Inc. bought a new position in Neurocrine Biosciences in the 4th quarter valued at about $33,000. Finally, Headinvest LLC acquired a new stake in Neurocrine Biosciences during the third quarter worth approximately $28,000. 92.59% of the stock is currently owned by institutional investors.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.